| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/24/2011 | EP2360142A1 N-substituted benzene sulfonamides |
| 08/24/2011 | EP2360139A2 Ferric organic compounds, uses thereof and methods of making same |
| 08/24/2011 | EP2360135A1 Method for manufacturing neuraminic acid derivatives |
| 08/24/2011 | EP2359868A1 Vector encoding human globulin gene and use thereof in treatment of hemoglobinopathies |
| 08/24/2011 | EP2359861A1 Inclusion complexes of pinocembrin with cyclodextrin or its derivatives |
| 08/24/2011 | EP2359860A2 Polymer micelle composition for treatment of resistant cancer cells |
| 08/24/2011 | EP2359859A1 Compositions comprising albumin nanoparticles and methods of delivery of pharmacological agents |
| 08/24/2011 | EP2359858A1 Nutritional composition comprising indigestible oligosaccharides |
| 08/24/2011 | EP2359857A2 Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth |
| 08/24/2011 | EP2359855A2 Methods of administering anti-TNFalpha antibodies |
| 08/24/2011 | EP2359852A1 Novel cancer targeting therapy using complex of substance capable of binding specifically to constituent factor of cancer stroma and anti-tumor compound |
| 08/24/2011 | EP2359840A1 Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy |
| 08/24/2011 | EP2359835A1 Viral infection therapeutic drug containing polyalkyleneimine |
| 08/24/2011 | EP2359834A1 Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
| 08/24/2011 | EP2359833A1 Antiviral phosphonate analogs |
| 08/24/2011 | EP2359832A2 Therapeutic agents targeting the NCCA-ATP channel and methods of use thereof |
| 08/24/2011 | EP2359831A2 Therapeutic applications of pro-apoptotic benzodiazepines |
| 08/24/2011 | EP2359830A1 Controlled released preparations of oxcarbazepine having sigmoidal release profile |
| 08/24/2011 | EP2359829A1 Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis |
| 08/24/2011 | EP2359828A1 HDAC inhibitors and hormone targeted drugs for the treatment of cancer |
| 08/24/2011 | EP2359827A1 Adhesive material containing 5-methyl-1-phenyl-2-(1h)-pyridone |
| 08/24/2011 | EP2359826A1 Combination of HMG-COA reductase inhibitors, such as roflumilast, roflumilast-N-oxide with a phosphodiesterase 4 inhibitor, rosuvastatin, for the treatment of inflammatory pulmonary diseases |
| 08/24/2011 | EP2359825A2 Combination drug |
| 08/24/2011 | EP2359824A1 Multiplication of the efficacy of anti-infectious agents by a composition comprising an extract made from dehydrated and partially sodium-free seawater |
| 08/24/2011 | EP2359823A1 Adhesive pharmaceutical preparation containing bisoprolol |
| 08/24/2011 | EP2359822A1 Treatment of cachexia |
| 08/24/2011 | EP2359821A1 Dosage regimen of an s1p receptor agonist |
| 08/24/2011 | EP2359820A1 Shunt delivery of curcumin for the treatment Alzneimer |
| 08/24/2011 | EP2359819A1 Substituted styryl benzylsulfones for treating proliferative disorders |
| 08/24/2011 | EP2359818A1 Combination of LBH589 with HSP 90 inhibitors for treating cancer |
| 08/24/2011 | EP2359816A1 Aripiprazole formulations |
| 08/24/2011 | EP2359815A1 Compositions comprising amlodipine and bisoprolol |
| 08/24/2011 | EP2359814A1 Pharmaceutical mini-tablets for sustained release of flecainide acetate |
| 08/24/2011 | EP2359813A1 Pharmaceutical composition comprising N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid |
| 08/24/2011 | EP2359812A1 Oral lyophilised compositions |
| 08/24/2011 | EP2359810A2 Pharmaceutical formulations comprising clopidogrel |
| 08/24/2011 | EP2359807A1 Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
| 08/24/2011 | EP2359701A1 Composition for improving membrane composition and functioning of cells |
| 08/24/2011 | EP2359688A1 Organ arrest, protection and preservation |
| 08/24/2011 | EP2358902A1 Compositions and methods for micro-rna expression profiling of cancer stem cells |
| 08/24/2011 | EP2358901A1 Use of p2x7 pathway for assessing the sensitivity of a subject to a cancer treatment |
| 08/24/2011 | EP2358877A2 Inhibition of vegf-a secretion, angiogenesis and/or neoangiogenesis by sina mediated knockdown of vegf-c and rhoa |
| 08/24/2011 | EP2358795A1 Surface modification of polymers via surface active and reactive end groups |
| 08/24/2011 | EP2358732A1 Method of synthesizing macrolide compounds |
| 08/24/2011 | EP2358731A2 Methods related to modified glycans |
| 08/24/2011 | EP2358730A1 High-purity rebaudioside d and applications |
| 08/24/2011 | EP2358725A1 Imidazolothiazole compounds as modulators of protein kinase |
| 08/24/2011 | EP2358724A1 Tiotropium bromide having a low degree of crystallinity |
| 08/24/2011 | EP2358723A1 Organic compounds |
| 08/24/2011 | EP2358722A1 Nitrogenous heterocyclic compounds, preparation thereof, and use thereof as antibacterial agents |
| 08/24/2011 | EP2358721A1 Modulators of cystic fibrosis transmembrane conductance regulator |
| 08/24/2011 | EP2358720A2 Fused ring heteroaryl kinase inhibitors |
| 08/24/2011 | EP2358719A1 Novel pyrroiol2,l-cu1.41benzodiazepine derivatives with dithiocarbamate side chains and process for the preparation thereof |
| 08/24/2011 | EP2358718A1 Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/p13k/akt pathway |
| 08/24/2011 | EP2358717A1 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 08/24/2011 | EP2358715A1 3-(3-pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyrimidine derivatives |
| 08/24/2011 | EP2358714A1 Alkylcyclohexylethers of dihydrotetraazabenzoazulenes |
| 08/24/2011 | EP2358713A1 Imidazopyridazine derivatives acting as orexin antagonists |
| 08/24/2011 | EP2358712A1 Piperidine derivatives useful as orexin receptor antagonists |
| 08/24/2011 | EP2358711A1 Piperidine derivatives useful as orexin receptor antagonists |
| 08/24/2011 | EP2358710A1 Akt and p70 s6 kinase inhibitors |
| 08/24/2011 | EP2358707A2 Compositions and methods for treatment of renin-angiotensin aldosterone system (raas)-related disorders |
| 08/24/2011 | EP2358706A1 [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
| 08/24/2011 | EP2358705A1 (r) -3- (e) -2- (pyrr0lidin-3-yl) vinyl) -5- (tetrahydr0pyran-4-yl0xy) pyridine, its salts, its synthesis and its use as ligand for nicotinic acetylcholinergic receptors |
| 08/24/2011 | EP2358704A1 7-azaspiro [3.5]nonane-7-carboxamide compounds as modulators of fatty acid amide hydrolase |
| 08/24/2011 | EP2358703A1 Tetrasubstituted pyridazines hedgehog pathway antagonists |
| 08/24/2011 | EP2358702A2 Piperidine compounds, pharmaceutical composition comprising the same and its use |
| 08/24/2011 | EP2358701A1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
| 08/24/2011 | EP2358698A1 Tetrasubstituted pyridazine hedgehog pathway antagonists |
| 08/24/2011 | EP2358697A1 Isoindoline compounds for use in the treatment of cancer |
| 08/24/2011 | EP2358694A1 Rocaglaol derivatives as cardioprotectant agents and as antineoplastic agents |
| 08/24/2011 | EP2358693A2 Preparation of docetaxel |
| 08/24/2011 | EP2358692A1 Cysteine protease inhibitors |
| 08/24/2011 | EP2358689A1 Benzothiazole derivatives as anticancer agents |
| 08/24/2011 | EP2358688A2 Antagonists of lysophosphatidic acid receptors |
| 08/24/2011 | EP2358686A1 Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
| 08/24/2011 | EP2358682A2 Isoquinolone derivatives as inhibitors of plavivirus replication |
| 08/24/2011 | EP2358681A1 Substituted 4-(1,2,3,4-tetrahydroisochinolin-2-yl)-4-oxo-butyric acid amide as kcnq2/2 modulators |
| 08/24/2011 | EP2358680A1 Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide |
| 08/24/2011 | EP2358677A1 Naphthylacetic acids used as crth2 antagonists or partial agonists |
| 08/24/2011 | EP2358676A1 Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound |
| 08/24/2011 | EP2358675A1 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds |
| 08/24/2011 | EP2358673A1 Novel bis-amides as antimalarial agents |
| 08/24/2011 | EP2358669A2 Alpha-keto peracids and methods for producing and using the same |
| 08/24/2011 | EP2358658A2 Preparation of rasagiline and salts thereof |
| 08/24/2011 | EP2358439A1 Methods for treating hepatitis c virus infection |
| 08/24/2011 | EP2358390A1 Cd37 immunotherapeutic combination therapies and uses thereof |
| 08/24/2011 | EP2358385A1 Agents and treatment for snoring and respiratory effort related arousals in sleep |
| 08/24/2011 | EP2358381A1 Compositions for potentiating apoposis signals in tumour cells |
| 08/24/2011 | EP2358380A1 Synthetic mimetics of host defense and uses thereof |
| 08/24/2011 | EP2358379A1 Biodefenses using triazole-containing macrolides |
| 08/24/2011 | EP2358378A2 Topical formulation(s) for the treatment of inflammation, skin and mucosal disorders and other diseases thereof |
| 08/24/2011 | EP2358373A1 Injectable polydeoxyribonucleotide composition for the treatment of osteoarticular diseases |
| 08/24/2011 | EP2358372A1 Microrna-mediated regulation of ubc9 expression in cancer cells |
| 08/24/2011 | EP2358371A1 P2x3, receptor antagonists for treatment of pain |
| 08/24/2011 | EP2358370A2 Treatment of proteinopathies using a farnesyl transferase inhibitor |
| 08/24/2011 | EP2358369A1 Process for the preparation of substantially optically pure repaglinide and precursors thereof |
| 08/24/2011 | EP2358368A1 Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy |
| 08/24/2011 | EP2358367A1 Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy |
| 08/24/2011 | EP2358366A1 Pharmacokinetically-based dosing regimens of a thrombin receptor antagonist |